Funded Project Details - FY2021
|Title:|| Assessment of cardiotoxicity in Immunity Checkpoint Blockers and other cancer therapies|
Mary S. Vaughan-Sarrazin
||Iowa City, IA
|Congressional District Code:
||Health Services R&D
|| September 2020 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Background: Lung cancer is a leading cause of death from cancer death worldwide, and non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Advances in NSCLC treatment using tyrosine kinase inhibitors (TKI) and immunity checkpoint blockers (ICB) have led to improved survival. However, there is a growing concern that cardiotoxicity associated with novel cancer therapies may lead to premature morbidity among survivors. Unfortunately, heart damage due to cardiotoxicity is oft...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.